Trius to Present at the BIO CEO & Investor Conference
February 07, 2012 16:01 ET
|
Trius Therapeutics, Inc.
SAN DIEGO, Feb. 7, 2012 (GLOBE NEWSWIRE) -- Trius Therapeutics, Inc. (Nasdaq:TSRX) announced today that Jeffrey Stein, Ph.D., President and Chief Executive Officer of Trius Therapeutics, will provide...
Trius Therapeutics, Inc. Announces Exercise in Full of Underwriters' Option to Purchase Additional Shares for Common Stock Offering
January 30, 2012 07:00 ET
|
Trius Therapeutics, Inc.
SAN DIEGO, Jan. 30, 2012 (GLOBE NEWSWIRE) -- Trius Therapeutics, Inc. (Nasdaq:TSRX) today announced that the underwriters of its public offering that priced on January 26, 2012 have exercised in full...
Trius Therapeutics, Inc. Prices Public Offering of Common Stock
January 26, 2012 09:04 ET
|
Trius Therapeutics, Inc.
SAN DIEGO, Jan. 26, 2012 (GLOBE NEWSWIRE) -- Trius Therapeutics, Inc. (Nasdaq:TSRX) today announced the pricing of an underwritten public offering of 8,600,000 shares of its common stock at a price to...
Trius Therapeutics, Inc. Announces Proposed Public Offering of Common Stock
January 25, 2012 16:00 ET
|
Trius Therapeutics, Inc.
SAN DIEGO, Jan. 25, 2012 (GLOBE NEWSWIRE) -- Trius Therapeutics, Inc. (Nasdaq:TSRX) today announced that it intends to offer and sell shares of its common stock in an underwritten public offering....
Trius Earns $5 Million Milestone Payment From Bayer for Successful Completion of First Phase 3 Trial of Tedizolid
January 23, 2012 07:00 ET
|
Trius Therapeutics, Inc.
SAN DIEGO, Jan. 23, 2012 (GLOBE NEWSWIRE) -- Trius Therapeutics, Inc. (Nasdaq:TSRX) announced today that it has earned a $5 million milestone payment from Bayer Healthcare for the achievement of all...
Trius Reports Positive Results From First Phase 3 Trial of Tedizolid in Acute Bacterial Skin and Skin Structure Infections
December 19, 2011 07:00 ET
|
Trius Therapeutics, Inc.
Tedizolid over 6 days of therapy achieved all primary and secondary efficacy endpoints versus 10 days of linezolid
Tedizolid demonstrated a lower incidence of adverse events
SAN DIEGO,...
Trius to Host Analyst and Investor Day in New York
November 28, 2011 16:00 ET
|
Trius Therapeutics, Inc.
SAN DIEGO, Nov. 28, 2011 (GLOBE NEWSWIRE) -- Trius Therapeutics, Inc. (Nasdaq:TSRX) announced today that the Company will host an analyst and investor day on Thursday, December 1 at 10:00 a.m. Eastern...
Trius to Present at Piper Jaffray Healthcare Conference
November 22, 2011 16:01 ET
|
Trius Therapeutics, Inc.
SAN DIEGO, Nov. 22, 2011 (GLOBE NEWSWIRE) -- Trius Therapeutics, Inc. (Nasdaq:TSRX) announced today that Jeffrey Stein, Ph.D., President and Chief Executive Officer of Trius Therapeutics, will provide...
Trius Therapeutics Reports 2011 Third Quarter Financial Results
November 10, 2011 16:01 ET
|
Trius Therapeutics, Inc.
SAN DIEGO, Nov. 10, 2011 (GLOBE NEWSWIRE) -- Trius Therapeutics, Inc. (Nasdaq:TSRX), a biopharmaceutical company focused on the discovery, development and commercialization of innovative antibiotics...
Trius to Present at Credit Suisse Healthcare Conference
November 07, 2011 16:01 ET
|
Trius Therapeutics, Inc.
SAN DIEGO, Nov. 7, 2011 (GLOBE NEWSWIRE) -- Trius Therapeutics, Inc. (Nasdaq:TSRX) announced today that Jeffrey Stein, Ph.D., President and Chief Executive Officer of Trius Therapeutics, will provide...